Uniphar's Total Assets for the quarter that ended in Dec. 2025 was £1,515 Mil.
Warning Sign:
If a company builds assets at 14.8% a year, faster than its revenue growth rate of 11.7% over the past 5 years, it means that the company may be getting less efficient.
During the past 12 months, Uniphar's average Total Assets Growth Rate was 18.00% per year.
During the past 3 years, the average Total Assets Growth Rate was 15.40% per year.
During the past 5 years, the average Total Assets Growth Rate was 14.80% per year.
During the past 10 years, Uniphar's highest 3-Year average Total Assets Growth Rate was 39.60%. The lowest was 14.80%. And the median was 15.90%.
Total Assets is connected with ROA %. Uniphar's annualizedROA % for the quarter that ended in Dec. 2025 was 4.14%. Total Assets is also linked to Revenue through Asset Turnover. Uniphar's Asset Turnover for the quarter that ended in Dec. 2025 was 0.98.
Note:
The Net Income data used here is two times the semi-annual (Dec. 2025) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Uniphar's Asset Turnover for the quarter that ended in Dec. 2025 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Uniphar Total Assets Related Terms
Uniphar Total Assets Historical Data
* Premium members only.
The historical data trend for Uniphar's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Uniphar's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Uniphar (LSE:UPR) has a Total Assets of £1,515 Mil as of Dec. 2025. The total amount of assets as recorded on a company's balance sheet. View historical data on Uniphar and its competitors.
Is Uniphar's Total Assets too high?
Uniphar's current Total Assets is £1,515 Mil. Overall, Uniphar has a GF Score™ of 84/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Uniphar's Total Assets compare to MCK and CAH?
Uniphar's Total Assets of £1,515 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Medical Distribution company?
A good Total Assets depends on the Medical Distribution industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Uniphar and its competitors. Uniphar's current Total Assets is £1,515 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Uniphar stock overvalued right now?
Based on GuruFocus' analysis, Uniphar (LSE:UPR) is currently considered Modestly Overvalued. The stock's GF Value™ is £3.03, compared to a current price of £3.93 — trading 29.7% above its estimated fair value. The current Total Assets is £1,515 Mil. Uniphar's overall GF Score™ is 84/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Uniphar (LSE:UPR), the current Total Assets is £1,515 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Uniphar (LSE:UPR) Overvalued in 2026?
Based on GuruFocus' analysis, Uniphar stock appears to be overvalued.
The current stock price of £3.93 is trading 29.7% above its estimated GF Value™ of £3.03.
GuruFocus considers Uniphar to be Modestly Overvalued.
Key valuation signals for LSE:UPR:
Total Assets: £1,515 Mil
GF Value™: £3.03 vs. price of £3.93 (29.7% above fair value)
No single metric tells the full story. See the LSE:UPR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Uniphar PLC is a service provider within the pharmaceutical and healthcare sector. The company is an international diversified healthcare services business servicing the requirements of multinational pharmaceutical and medical technology manufacturers across three divisions - Uniphar Pharma, Uniphar Medtech and Uniphar Supply Chain & Retail. Uniphar Pharma enables pharma and biotech companies to bring medicines to markets globally and provide healthcare professionals with access to medicines that can't be sourced through traditional channels. Uniphar Medtech is a Pan-European medical device distributor and solutions partner. Uniphar Supply Chain & Retail is the pharmaceutical wholesaler in Ireland offering of retail pharmacies.
84GF Score
Get the complete analysis for LSE:UPR
Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:UPR has been successfully added to your 
